A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages.
OBJECTIVE
To compare the effect of aspirin and enoxaparin on live births in women with unexplained recurrent miscarriages, as well as secondary outcomes including birth weight, uterine and umbilical blood flows, and congenital malformations.


METHODS
Multicenter randomized comparative cohort study.


METHODS
Four centers including two university hospitals, a peripheral general hospital, and a community health clinic.


METHODS
One hundred seven patients were randomized, 104 were available for analysis; 54 were randomized to enoxaparin and 50 to aspirin.


METHODS
Treatment with enoxaparin or aspirin in subsequent pregnancy.


METHODS
Subsequent live births or miscarriage, and the incidence of obstetric complications.


RESULTS
Both groups had a similar live birth rate (relative risk = 0.92, 95% confidence interval: 0.58-1.46). In primary aborters, live births occurred in 17 of 18 (94%) enoxaparin-treated pregnancies compared to 18 of 22 (81%) aspirin-treated pregnancies. In the aspirin group, two pregnancies were terminated: for tricuspid insufficiency and for hemolysis, elevated liver enzymes, low platelet (HELLP) syndrome. One enoxaparin-treated infant was growth restricted (2,020 g) at 36 weeks. Preeclampsia was found in three aspirin-treated patients. Preterm delivery, placental Doppler blood flow, apgar scores, and mean birth weights were similar in both groups. In the aspirin group, one infant underwent orchidectomy after testicular torsion in utero, and one infant had hypoglycemia and convulsions.


CONCLUSIONS
Both regimens were associated with a high live birth rate and few late pregnancy complications.
Dolitzky
Mordechai
M
Department of Obstetrics & Gynecology, Sheba Medical Center, Tel Hashomer, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Inbal
Aida
A
Segal
Yakov
Y
Weiss
Amir
A
Brenner
Benjamin
B
Carp
Howard
H
D000026:Abortion, Habitual / Q000188:drug therapy*; D000028:Abortion, Induced; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D001723:Birth Rate; D001724:Birth Weight; D017984:Enoxaparin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000453:epidemiology; D050498:Live Birth; D008875:Middle Aged; D007752:Obstetric Labor, Premature / Q000453:epidemiology; D010920:Placenta / Q000098:blood supply / Q000000981:diagnostic imaging; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000453:epidemiology; D012039:Regional Blood Flow; D014463:Ultrasonography
D000925:Anticoagulants; D017984:Enoxaparin; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin